ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2016; 6(7):1004-1011. doi:10.7150/thno.14471 This issue Cite
Research Paper
Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors
1. Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, U.S.A.
2. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
3. Shiley Eye Institute, University of California, San Diego, La Jolla, CA 92093, U.S.A.
4. Department of Pediatric Research, MD Anderson Cancer Center, Houston, TX 77030, U.S.A.
Citation:
Luk BT, Fang RH, Hu CMJ, Copp JA, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics 2016; 6(7):1004-1011. doi:10.7150/thno.14471. https://www.thno.org/v06p1004.htm
Other stylesAbstract
The therapeutic potential of nanoparticle-based drug carriers depends largely on their ability to evade the host immune system while delivering their cargo safely to the site of action. Of particular interest are simple strategies for the functionalization of nanoparticle surfaces that are both inherently safe and can also bestow immunoevasive properties, allowing for extended blood circulation times. Here, we evaluated a recently reported cell membrane-coated nanoparticle platform as a drug delivery vehicle for the treatment of a murine model of lymphoma. These biomimetic nanoparticles, consisting of a biodegradable polymeric material cloaked with natural red blood cell membrane, were shown to efficiently deliver a model chemotherapeutic, doxorubicin, to solid tumor sites for significantly increased tumor growth inhibition compared with conventional free drug treatment. Importantly, the nanoparticles also showed excellent immunocompatibility as well as an advantageous safety profile compared with the free drug, making them attractive for potential translation. This study demonstrates the promise of using a biomembrane-coating approach as the basis for the design of functional, safe, and immunocompatible nanocarriers for cancer drug delivery.
Keywords: nanomedicine, biomimetic nanoparticle, immunocompatible nanocarrier, drug delivery, lymphoma treatment.
Citation styles
APA
Luk, B.T., Fang, R.H., Hu, C.M.J., Copp, J.A., Thamphiwatana, S., Dehaini, D., Gao, W., Zhang, K., Li, S., Zhang, L. (2016). Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics, 6(7), 1004-1011. https://doi.org/10.7150/thno.14471.
ACS
Luk, B.T.; Fang, R.H.; Hu, C.M.J.; Copp, J.A.; Thamphiwatana, S.; Dehaini, D.; Gao, W.; Zhang, K.; Li, S.; Zhang, L. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics 2016, 6 (7), 1004-1011. DOI: 10.7150/thno.14471.
NLM
Luk BT, Fang RH, Hu CMJ, Copp JA, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics 2016; 6(7):1004-1011. doi:10.7150/thno.14471. https://www.thno.org/v06p1004.htm
CSE
Luk BT, Fang RH, Hu CMJ, Copp JA, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. 2016. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics. 6(7):1004-1011.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.